NM health department warns of risk from dust storms
A dust storm temporarily closed I25 at La Bajada Hill. on March 18, 2025. (George Ducker, NM Forestry Division )
Dust storms, such as the one New Mexico experienced on Tuesday, don't just pose visibility risks on the road. The New Mexico Department of Health on Wednesday issued an advisory on the potential health risks dust storms carry, aimed particularly for residents living in Doña Ana and Luna counties.
Those counties, a news release noted, typically average 10 days annually when dust storms cause exceedances of the National Ambient Air Quality Standard for airborne particulate matter of 10 microns or less in size.
'Dust storms may be common in our region, and the health risks they pose are significant,' DOH Chief Medical Officer Dr. Miranda Durham said in a statement. 'The microscopic particles can trigger respiratory issues, particularly for vulnerable people. We urge residents to limit outdoor exposure during dust events and take appropriate precautions to protect their health.'
Inhaling dust isn't good for anyone. 'Coarse dust particles can irritate the lungs, which may trigger asthma attacks and allergic reactions, especially for those with underlying respiratory issues. Some groups run particularly high risk, including:
• infants, children, and teens.
• elderly.
• people with respiratory conditions like asthma, bronchitis, COPD and emphysema.
• people with existing heart or lung disease.
• pregnant women
Avoiding outdoor activity during dust storms or, if unavoidable, wearing protective covering is advised. More information on the risks of dust storms can be found here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
3 hours ago
- Indianapolis Star
First Knozone Action Day of 2025: Outside air will be bad June 12. What you should know
The first Knozone Action Day has been issued for June 12, 2025. Hot temperatures, sunny skies, and light winds will lead to conditions suitable for ozone development when combined with wildfire smoke and other emission sources. Due to a high ground-level ozone forecast, the air quality outside will be deemed unhealthy for sensitive groups. The Indianapolis Office of Sustainability said people in Central Indiana with asthma, chronic obstructive pulmonary (COPD) disease, and other similar diagnoses should avoid time spent outdoors on June 12. Unhealthy air quality impacts public health and environmental justice as vulnerable groups, including children, older adults, pregnant people, outdoor laborers, and anyone suffering from asthma, COPD, emphysema, heart disease, or other conditions, are at greater risk, according to the office. Nearly 1 in 5 Marion County residents is at greater risk for severe symptoms due to unhealthy air quality. People can sign up at to be notified of unhealthy air days early. and the Environmental Protection Agency's AirNow website and mobile app are other resources for monitoring local air. This time last year: Stay inside, Knozone Action Day extended due to high temperatures Knozone Action Days happen when levels of certain pollutants rise above acceptable thresholds. During Knozone Action Days, the air quality may become unhealthy for sensitive individuals due to increased ground-level ozone and/or fine particles, which are two of the most common pollutants in the United the ozone layer high in the atmosphere helps protect us from the sun's rays, ozone down where we breathe is dangerous for public health, according to the Office of Sustainability. Ground-level ozone is created when a chemical reaction occurs between sunlight and hydrocarbons from emission sources common in urban areas, like gas-powered vehicles and lawn mowers. Fine particulate matter (or PM2.5) refers to microscopic particles in the air, including dust and smoke, that we can inhale into our lungs and cause damage. This can even be caused by wildfires or dust clouds blowing from thousands of miles away. Residents are encouraged to reduce their contribution toground-level ozone by:
Yahoo
13 hours ago
- Yahoo
Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in Pulmonary Pharmacology and Therapeutics
REYKJAVIK, Iceland, June 11, 2025--(BUSINESS WIRE)--EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled pathogens, has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics. These publications describe the potential for EpiEndo's lead asset EP395, also known as 'glasmacinal', to be of therapeutic benefit in the treatment of COPD and support its continued clinical development. The article "Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial" reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. The paper was co-authored with investigators from Fraunhofer Institute for Toxicology and Experimental Medicine who conducted the study. The second article, "Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation" describes preclinical data that demonstrate EP395 has comparable inhibitory effects on acute neutrophilic airway inflammation to azithromycin, which is used chronically off-label for its immunomodulatory properties to reduce COPD exacerbations. Finally, "A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier" reports that EP395 has negligible antibiotic activity and enhances the barrier function of the respiratory epithelium. Maria Bech, CEO of EpiEndo Pharmaceticals commented: "It is great to see the publication of this clinical and pre-clinical research in a peer-reviewed journal, highlighting the efficacy we are seeing with glasmacinal in neutrophilic inflammation. "The anti-inflammatory effects of glasmacinal are comparable to those seen with azithromycin preclinically, but without anti-microbial activity. The clinical LPS study shows that EP395 enhances the host defence response to inhaled challenge, supporting our hypothesis that glasmacinal could be effective in reducing exacerbations in COPD but without developing anti-microbial resistance. "We continue to develop glasmacinal as a potential new oral treatment option for COPD patients, aiming to bring additional therapeutic options to patients with chronic respiratory diseases." Professor Clive Page, Emeritus Professor of Pharmacology, King's College London and Chairman of EpiEndo Pharmaceutical's Scientific Advisory Board added: "These exciting new data demonstrate glasmacinal's effect on neutrophilic inflammation both in a clinical study and in established non-clinical models of airways disease. These novel findings, coupled with data presented at ERS in 2024 on EP395's anti-inflammatory effect on eosinophilic inflammation (caused by allergens), demonstrate the broad anti-inflammatory activity of this drug that has the potential to provide a novel, groundbreaking approach to treat patients with COPD, irrespective of their type of inflammation." About EpiEndo Pharmaceuticals ( EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders. EpiEndo's new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as 'Barriolides™', show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo's lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution. Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030. View source version on Contacts EpiEndo Pharmaceuticals: Maria Bech, CEO+354 454 0090 Vigo Consulting (media relations):Rozi Morris+44 20 7390 0230epiendo@ Sign in to access your portfolio
Business Wire
13 hours ago
- Business Wire
Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in
REYKJAVIK, Iceland--(BUSINESS WIRE)--EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled pathogens, has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics. These publications describe the potential for EpiEndo's lead asset EP395, also known as 'glasmacinal', to be of therapeutic benefit in the treatment of COPD and support its continued clinical development. The article 'Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial' reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. The paper was co-authored with investigators from Fraunhofer Institute for Toxicology and Experimental Medicine who conducted the study. The second article, 'Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation' describes preclinical data that demonstrate EP395 has comparable inhibitory effects on acute neutrophilic airway inflammation to azithromycin, which is used chronically off-label for its immunomodulatory properties to reduce COPD exacerbations. Finally, 'A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier ' reports that EP395 has negligible antibiotic activity and enhances the barrier function of the respiratory epithelium. Maria Bech, CEO of EpiEndo Pharmaceticals commented: 'It is great to see the publication of this clinical and pre-clinical research in a peer-reviewed journal, highlighting the efficacy we are seeing with glasmacinal in neutrophilic inflammation. 'The anti-inflammatory effects of glasmacinal are comparable to those seen with azithromycin preclinically, but without anti-microbial activity. The clinical LPS study shows that EP395 enhances the host defence response to inhaled challenge, supporting our hypothesis that glasmacinal could be effective in reducing exacerbations in COPD but without developing anti-microbial resistance. 'We continue to develop glasmacinal as a potential new oral treatment option for COPD patients, aiming to bring additional therapeutic options to patients with chronic respiratory diseases.' Professor Clive Page, Emeritus Professor of Pharmacology, King's College London and Chairman of EpiEndo Pharmaceutical's Scientific Advisory Board added: 'These exciting new data demonstrate glasmacinal's effect on neutrophilic inflammation both in a clinical study and in established non-clinical models of airways disease. These novel findings, coupled with data presented at ERS in 2024 on EP395's anti-inflammatory effect on eosinophilic inflammation (caused by allergens), demonstrate the broad anti-inflammatory activity of this drug that has the potential to provide a novel, groundbreaking approach to treat patients with COPD, irrespective of their type of inflammation.' About EpiEndo Pharmaceuticals ( EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders. EpiEndo's new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as 'Barriolides™', show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo's lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution. Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030.
